The SAPPHIRE Study (Systolic And Pulse Pressure Hemodynamic Improvement By Restoring Elasticity)
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment
of isolated systolic hypertension in a formal dose-ranging study in patients without left
ventricular hypertrophy. Eligible patients will be randomized to double-blind treatment once
daily for 6 months with oral ALT-711 (35, 70, 140, or 210 mg) or placebo.